All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Any worries by Promedior Inc. investors after Bristol-Myers Squibb Co. (BMS) backed away last year from its option to acquire the firm were resolved in a big way by last week's news that Roche Holding AG is taking over the company in a transaction valued as high as $1.39 billion. Privately held, Lexington, Mass.-based Promedior's lead asset is PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that won breakthrough designation from the FDA earlier this year for idiopathic pulmonary fibrosis (IPF).
CEO David Giljohann said the first indication in Exicure Inc.'s deal with Allergan plc is antigenic alopecia, but his firm doesn't "have anything else to disclose yet" about other hair loss diseases that the pact will include.
Merck & Co. Inc. acquired Calporta Therapeutics Inc. for an up-front payment and milestone payments that could total $576 million. Calporta is a build-to-buy spinout of La Jolla, Calif.-based COI Pharmaceuticals Inc. Calporta develops selective small-molecule agonists to TRPML1, foremost in the mammalian mucolipin TRP channel subfamily.
HONG KONG – South Korea's Samsung Bioepis Co. Ltd. will get $100 million in up-front payments in a commercialization deal for two of its biosimilar candidates with U.S. company Biogen Inc. Under the deal, Samsung Bioepis will also be eligible for up to $270 million in milestone and option payments, as well as a share of sales revenue.
DUBLIN – Evotec SE is taking a further crack at kidney disease, through a 50-50 joint venture with Vifor Pharma Group, which is funding an initial drug discovery and preclinical development phase with €25 million (US$27.6 million). The as-yet-unnamed venture aims to capitalize on Evotec's participation in a large-scale U.K. biobank, which is tracking about 4,000 patients with either chronic kidney disease or idiopathic nephrotic syndrome.
When the time was right to make a powerful Western biotech welcome in China, Beigene Ltd. was ready when Amgen Inc. came calling. Its massive $2.7 billion cash equity investment in Beigene buys Amgen an oncology footprint in China.
HONG KONG – Canadian company Pascal Biosciences Inc., headquartered in Vancouver, and South Korean biotech Y-biologics Inc., based in Daejeon, have signed a research collaboration agreement for the discovery and development of bispecific antibodies for the treatment of leukemia.
South Korean AI-based biotech Azoth Bio Inc., of Seongnam, Gyeonggi-do, and biopharmaceutical venture Wellmarker Bio Co. Ltd., based in Seoul, have signed a memorandum of understanding for cancer drug R&D and commercialization.
San Clemente, Calif.-based ICU Medical Inc. has acquired Minneapolis-based Pursuit Vascular Inc. for $75 million and an additional, undisclosed earn-out payment that would be due in 2021. In the deal, it gains the Clearguard HD Antimicrobial Barrier Cap, which is the only U.S.-marketed device that's been shown to reduce central line-associated bloodstream infections in hemodialysis patients.
Allogene Therapeutics Inc., a South San Francisco-based company developing off-the-shelf allogeneic T-cell therapies for cancer, is taking a 25% stake in Notch Therapeutics Inc., paying the Canadian startup $10 million up front in an exclusive deal to research and develop new induced pluripotent stem cell (IPSC)-based CAR T therapies. The partners will initially focus on developing next-generation treatments for non-Hodgkin lymphoma (NHL), leukemia and multiple myeloma.
RSS
